Login to Your Account

BTG Gets 'Sentiment Boost' With Voraxaze Nod in U.S.

By Nuala Moran
BioWorld Today Correspondent

Thursday, January 19, 2012
LONDON – BTG plc is celebrating its first regulatory approval after the FDA gave the nod to Voraxaze, an antidote to the chemotherapeutic methotrexate.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription